WallStSmart

Empro Group Inc. Ordinary shares (EMPG)vsMcKesson Corporation (MCK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McKesson Corporation generates 7493163% more annual revenue ($410.98B vs $5.48M). EMPG leads profitability with a 13.7% profit margin vs 1.1%. MCK trades at a lower P/E of 23.6x. EMPG earns a higher WallStSmart Score of 47/100 (D+).

EMPG

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 9.0Value: 4.0Quality: 7.5
Piotroski: 6/9Altman Z: 3.11

MCK

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 4.5Value: 4.0Quality: 7.0
Piotroski: 5/9Altman Z: 5.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EMPG.

MCKSignificantly Overvalued (-60.4%)

Margin of Safety

-60.4%

Fair Value

$594.29

Current Price

$881.51

$287.22 premium

UndervaluedFair: $594.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EMPG4 strengths · Avg: 10.0/10
Return on EquityProfitability
49.2%10/10

Every $100 of equity generates 49 in profit

Operating MarginProfitability
36.1%10/10

Strong operational efficiency at 36.1%

Revenue GrowthGrowth
141.6%10/10

Revenue surging 141.6% year-over-year

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

MCK3 strengths · Avg: 9.7/10
Debt/EquityHealth
-2.7610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.4010/10

Safe zone — low bankruptcy risk

Market CapQuality
$102.78B9/10

Large-cap with strong market position

Areas to Watch

EMPG4 concerns · Avg: 3.3/10
Price/BookValuation
17.0x4/10

Trading at 17.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$143.05M3/10

Smaller company, higher risk/reward

P/E RatioValuation
192.9x2/10

Premium valuation, high expectations priced in

MCK4 concerns · Avg: 3.3/10
PEG RatioValuation
1.664/10

Expensive relative to growth rate

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
1.1%3/10

1.1% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : EMPG

The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.

Bull Case : MCK

The strongest argument for MCK centers on Debt/Equity, Altman Z-Score, Market Cap.

Bear Case : EMPG

The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.

Bear Case : MCK

The primary concerns for MCK are PEG Ratio, Return on Equity, Profit Margin. Thin 1.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

EMPG profiles as a growth stock while MCK is a value play — different risk/reward profiles.

EMPG is growing revenue faster at 141.6% — sustainability is the question.

EMPG generates stronger free cash flow (-16,470), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EMPG scores higher overall (47/100 vs 43/100) and 141.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Empro Group Inc. Ordinary shares

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.

Visit Website →

McKesson Corporation

HEALTHCARE · MEDICAL DISTRIBUTION · USA

McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.

Visit Website →

Want to dig deeper into these stocks?